Alexion and Stealth BioTherapeutics Corp have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy – a genetic mitochondrial disease – elamipretide is a novel, potential first-in-class therapy… more
Separately, Alexion has announced the appointment of Tanisha Carino, Ph.D., as Executive Vice President and the company’s first Chief Corporate Affairs Officer… more